BioGenCell Completes $16M in Seed Funding
Summary
Founded by Dr. Yael Porat and Prof. Michael Belkin, BioGenCell is a biotechnology company that develops technology for using stem cells from the patient’s own blood to treat microvascular diseases. The current product treats severe limb-threatening ischemia (CLI) typically found in patients with diabetes and heavy smokers. As part of the treatment, stem and other cells taken from the patient in a standard blood draw are manipulated under the patented process and then reinjected into the leg muscle. In its Phase I clinical trials, BioGenCell treated five patients who had previously tried all the other available treatments and were about to undergo leg amputation. The company recently received FDA permission to continue to Phase II controlled, double-blind trials.
Funding
Review available funding amount, funding date, investors, and linked company information related to BioGenCell Completes $16M in Seed Funding in the interactive ISVWorld profile.